key: cord-1041686-qvhig982
authors: Jha, Niharika
title: Cutaneous Manifestations of COVID-19 Observed in Indian Patients: A Case Series
date: 2021-11-22
journal: Indian Dermatol Online J
DOI: 10.4103/idoj.idoj_836_20
sha: 2f7b38908947064ab81f4f5ed2a5d30df7b2d959
doc_id: 1041686
cord_uid: qvhig982

nan

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com home isolation. The lesions subsided completely in 2 weeks without any residual pigmentation.

A 31-year-old female presented to the OPD with complaints of a gradually progressive, red-colored rash on the neck, trunk, and upper limbs for the past 3 to 4 days. She presented with a history of high-grade fever, malaise, breathlessness (even at rest), excruciating headache, retro-orbital pain, and loss of appetite for a period of 8 to 10 days. On examination, non-palpable purpura was noted over the neck, chest, abdomen, back, upper limbs, and palms with islands of sparing noticed on the back. Pseudo-vesiculation was seen in purpuric lesions on the back [Figures 2a, b and 3 ]. A preliminary diagnosis of dengue rash was made. The platelet count was 100,000/mm 3 , and all other routine investigations were within normal limits. Lactate dehydrogenase, erythrocyte sedimentation rate, D-dimer and C-reactive protein levels were raised. Serum ferritin was within normal limits. NS1 antigen test for dengue was negative. Chest X-ray posterioranterior view revealed peripheral and lower lobar predominant air space opacities and haziness, suggestive of COVID pneumonitis in the current scenario. RAT was negative, but reverse-transcriptase polymerase chain reaction (RT-PCR) was positive. The patient was referred to an advanced center for hospitalization. For cutaneous lesions, the patient was advised levocetirizine tablet 5 mg HS, betamethasone dipropionate cream, and an emollient for local application twice a day. On reviewing the discharge papers, we found that she was treated using paracetamol tablet 500 mg TDS (thrice a day; till the fever subsided), hydroxychloroquinone tablet 200 mg BD (twice a day), enoxaparin injection 4 mg s.c. (subcutaneous) BD for 2 weeks. Azithromycin tablet (500 mg) OD (once a day) was also given for 5 days. Oxygen support was given for breathlessness and inability to maintain the oxygen saturation (SpO 2 ). She was discharged after 17 days. The rash completely subsided in about 3 weeks from its appearance.

A diabetic and hypertensive 70-year-old male had low-grade fever, malaise, dry cough, and anosmia for 4 days. RAT was negative, but RT-PCR was positive. The patient was hospitalized for observation and was managed symptomatically. The patient developed an itchy, red-colored, evanescent rash on the trunk and extremities on the 10 th day of hospitalization that persisted even after the patient was discharged. On examination, wheals were present, predominantly on the trunk [ Figure 4 ]. The persistence of wheals even after stopping medications ruled out the possibility of a drug-induced urticaria. A diagnosis of acute urticaria following COVID-19 was made. He was started on levocetirizine tablet 5 mg HS and calamine lotion, and was relieved of his symptoms within 3 weeks.

A 29-year-old female, known case of chronic spontaneous urticaria, previously controlled on levocetirizine tablet 5 mg HS, with no other comorbidities, presented to our OPD with complaints of fever along with exacerbation of urticaria for 2 days. The dose of levocetirizine was increased to 5 mg BD and paracetamol tablet 500 mg SOS (if required) was added for fever. The patient did not get relief from her symptoms. She also complained of malaise and weakness. She was started on a tapering dose of prednisolone tablet starting from 0.5 mg/kg/day (30 mg). Basic routine investigations along with RAT were advised, which were within normal limits. RT-PCR was positive. The patient was advised home isolation. She recovered without sequelae within 2 weeks.

We have described cutaneous manifestations in four patients who were diagnosed with COVID-19 (COVID toes, purpura, and urticaria). All patients who had COVID-like symptoms and cutaneous manifestations were first subjected to RAT; if found negative, RT-PCR was done. In three patients, other symptoms preceded cutaneous manifestations. In one patient, the lesions and COVID-19 symptoms appeared together. The patient who developed purpuric lesions required oxygen support and prolonged hospitalization, the other three had mild symptoms. All the patients recovered without any sequelae. All the relevant details along with the probable pathogenesis have been included in Table 1 .

Dermatologists from the West have noted morbilliform rash, urticaria, pernio-like lesions, livedo-reticularis-like lesions, purpura, polymorphic rash as noticed in Kawasaki disease, and vesicular lesions in COVID-19 patients. [3, 4] Suspected COVID patients with negative RAT should be advised RT-PCR for confirmation. COVID patients can present directly to the dermatology OPD. It is imperative for all health care workers to take the required precautions while examining patients.

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Nil.

There are no conflicts of interest. Complement-induced microvascular injury [6] 70/M Urticaria 2 weeks after onset of systemic symptoms

Tab. levocetirizine (5mg) HS and calamine lotion L/A BD Recovered in 3 weeks without any sequelae Viral infection-induced nonimmune urticaria [7] Antigen-antibody complex deposition in vascular wall, followed by complement activation and mast cell degranulation [8] 29/F Exacerbation of previously controlled chronic spontaneous urticaria.

Along with systemic symptoms.

Tapering dose of Tab. prednisolone.

Recovered in 2 weeks.

Antigen-antibody complex deposition in vascular wall, followed by complement activation and mast cell degranulation COVID=Coronavirus disease, F=Female, M=Male, Tab. = Tablet, L/A=Local application, HS=At bedtime, BD=Twice daily

Fields Virology

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Cutaneous signs in COVID-19 patients: A review

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study

COVID toes: Where do we stand with the current evidence?

Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19

Urticaria and infections

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis